Your shopping cart is currently empty

Neuronostatin-13 human acetate is a 13-amino acid peptide hormone, which plays an important role in the regulation of hormonal and cardiac function.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $203 | Inquiry | Inquiry | |
| 5 mg | $613 | Inquiry | Inquiry | |
| 10 mg | $921 | Inquiry | Inquiry | |
| 25 mg | $1,653 | Inquiry | Inquiry | |
| 50 mg | $2,479 | Inquiry | Inquiry | |
| 100 mg | $3,722 | Inquiry | Inquiry | |
| 200 mg | $5,598 | Inquiry | Inquiry |
| Description | Neuronostatin-13 human acetate is a 13-amino acid peptide hormone, which plays an important role in the regulation of hormonal and cardiac function. |
| In vitro | Treatment with Neuronostatin-13 human acetate (1,000 nM) enhances low-glucose-induced glucagon release compare with islets treated with control medium alone. Treatment with Neuronostatin-13 human acetate for 1 h leads to a significant increase in the accumulation of glucagon mRNA compare with vehicle-treated control cells. In αTC1-9 α-cells, treatment with 100 nM Neuronostatin-13 human acetate leads to an increase in phosphorylated PKA at 30 and 40 min[1]. |
| In vivo | Infusion with Neuronostatin-13 human acetate delays glucose clearance in the rat model, such that blood glucose levels in Neuronostatin-13 human acetate-treated animals are significantly higher at 1 and 10 min following intra-arterial injection of a glucose bolus[1]. Chocardiographic measurement reveals a remarkable drop in heart rate after 3-, 6- and 12-hr of Neuronostatin-13 human acetate challenge. In addition, Neuronostatin-13 human acetate treatment significantly decreases left ventricular end-systolic diameter (LVESD) and fractional shortening without affecting left ventricular end-diastolic diameter (LVEDD) between 6 and 12 hrs following Neuronostatin-13 human acetate challenge, the effect of which returns to basal level 18-hr after Neuronostatin-13 human acetate treatment[2]. |
| Synonyms | Neuronostatin-13 human acetate(1096485-24-3 free base) |
| Molecular Weight | 1475.73 |
| Formula | C66H114N20O18 |
| Smiles | C[C@@H](C(N)=O)NC([C@H](C)NC([C@H](C)NC([C@H](C)NC([C@H](CC(C)C)NC([C@H](CO)NC([C@H](CCCCN)NC([C@H](CCC(N)=O)NC([C@H](CC(C)C)NC([C@H](CC1=CC=CC=C1)NC([C@H](CCC(N)=O)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)N)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O.CC(O)=O |
| Relative Density. | no data available |
| Sequence | H-Leu-Arg-Gln-Phe-Leu-Gln-Lys-Ser-Leu-Ala-Ala-Ala-Ala-NH2 |
| Sequence Short | LRQFLQKSLAAAA |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.